BRAF V600E melanoma patients, despite initial response to anti-BRAF V600E therapy, often relapse due to drug resistance. This study designs individualized melanoma combination treatments based on personalized network alterations using an information-theoretic approach. High-resolution patient-specific altered signaling signatures are computed, consisting of co-expressed subnetworks. Smart, personalized drug combinations (often FDA-approved) are designed based on these signatures, showing superior efficacy in vitro and in vivo compared to standard therapies. This approach is highly selective, and broadly applicable for designing patient-specific anti-melanoma drug combinations.
Publisher
npj Precision Oncology
Published On
Jun 10, 2021
Authors
S. Vasudevan, E. Flashner-Abramson, Heba Alkhaiti, Sangita Roy Chowdhury, I. A. Adejumobi, D. Vlienski, S. Stefansky, A. M. Rubinstein, N. Kravchenko-Balasha
Tags
BRAF V600E
melanoma
drug resistance
personalized medicine
combination therapy
signaling signatures
FDA-approved drugs
Related Publications
Explore these studies to deepen your understanding of the subject.
